1-(4-((4-benzylphenyl)carbamoyl)-3-fluorobenzyl)azetidine-3-carboxylic acid | 1133948-22-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-((4-benzylphenyl)carbamoyl)-3-fluorobenzyl)azetidine-3-carboxylic acid
• 英文别名: 1-[[4-[(4-Benzylphenyl)carbamoyl]-3-fluorophenyl]methyl]azetidine-3-carboxylic acid
• CAS: 1133948-22-7
• 化学式: C₂₅H₂₃FN₂O₃
• 分子量: 418.468
• InChiKey: XMRXCHFJULTADQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF
  申请人：Neira Susana C.

  公开号：US20090082331A1

  公开（公告）日：2009-03-26

  The present invention relates to amides that have activity as SIP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及具有SIP受体调节剂活性的酰胺，以及利用这些化合物治疗与不当S1P受体活性相关的疾病。这些化合物可用作免疫调节剂，例如，用于治疗或预防自身免疫和相关免疫紊乱性疾病，包括系统性红斑狼疮、克罗恩病和溃疡性结肠炎等炎症性肠病、I型糖尿病、葡萄膜炎、银屑病、重症肌无力、类风湿关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及用于治疗其他疾病。
• S1P Receptor Modulating Compounds and Use Thereof
  申请人：Neira Susana C.

  公开号：US20120088749A1

  公开（公告）日：2012-04-12

  The present invention relates to amides that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

  本发明涉及具有S1P受体调节剂活性的酰胺化合物，以及使用这些化合物治疗与不适当的S1P受体活性相关的疾病。这些化合物可以用作免疫调节剂，例如用于治疗或预防自身免疫和相关免疫性疾病，包括系统性红斑狼疮、克罗恩病和溃疡性结肠炎、1型糖尿病、葡萄膜炎、牛皮癣、重症肌无力、类风湿性关节炎、非肾小球性肾病、肝炎、Behçet病、肾小球肾炎、慢性血小板减少性紫癜、溶血性贫血、肝炎和Wegner肉芽肿；以及治疗其他疾病的条件。
• 1-(4-(4-BENZYLBENZAMIDO)-BENZYL)AZETIDINE-3-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS AS S1P RECEPTOR MODULATORS FOR THE TREATMENT OF IMMUNE DISORDERS
  申请人：Amgen Inc.

  公开号：EP2188252A2

  公开（公告）日：2010-05-26
• US8080542B2
  申请人：——

  公开号：US8080542B2

  公开（公告）日：2011-12-20
• [EN] S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS DE MODULATION DES RÉCEPTEURS S1P ET LEUR UTILISATION
  申请人：AMGEN INC

  公开号：WO2009038759A2

  公开（公告）日：2009-03-26

  The present invention relates to amides that have activity as SlP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate SlP receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non- glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.